Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Brentuximab vedotin is a drug immunoconjugate with an antibody targeting CD30, an antigen expressed mainly on Hodgkin's and anaplastic large-cell lymphomas, linked to a potent microtubule inhibitor. In a study involving 45 patients after relapse, 11 complete remissions were observed. Approximat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2010-11, Vol.363 (19), p.1812-1821
Hauptverfasser: Younes, Anas, Bartlett, Nancy L, Leonard, John P, Kennedy, Dana A, Lynch, Carmel M, Sievers, Eric L, Forero-Torres, Andres
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Brentuximab vedotin is a drug immunoconjugate with an antibody targeting CD30, an antigen expressed mainly on Hodgkin's and anaplastic large-cell lymphomas, linked to a potent microtubule inhibitor. In a study involving 45 patients after relapse, 11 complete remissions were observed. Approximately 15 to 30% of patients with Hodgkin's lymphoma do not have a long-term remission with conventional therapy, 1 resulting in an estimated 1300 deaths annually in the United States alone. 2 Autologous hematopoietic stem-cell transplantation (ASCT) represents a potentially curative treatment for some patients with recurrent or progressive Hodgkin's lymphoma after failure of initial combination chemotherapy. Unfortunately, ASCT is only effective in approximately 50% of such patients. 3 , 4 Among those who have a relapse after ASCT, overall survival is 55% at 2 years and 32% at 5 years. 5 Because the incidence of Hodgkin's lymphoma peaks during young adulthood, these premature deaths . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1002965